Growth Metrics

AtriCure (ATRC) Cash & Current Investments (2016 - 2025)

AtriCure (ATRC) has disclosed Cash & Current Investments for 16 consecutive years, with $167.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 36.43% to $167.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.4 million, a 36.43% increase, with the full-year FY2025 number at $167.4 million, up 36.43% from a year prior.
  • Cash & Current Investments was $167.4 million for Q4 2025 at AtriCure, up from $147.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $227.2 million in Q1 2021 to a low of $99.9 million in Q1 2025.
  • A 5-year average of $131.9 million and a median of $122.7 million in 2022 define the central range for Cash & Current Investments.
  • Biggest YoY gain for Cash & Current Investments was 231.51% in 2021; the steepest drop was 51.24% in 2021.
  • AtriCure's Cash & Current Investments stood at $119.1 million in 2021, then rose by 1.7% to $121.1 million in 2022, then rose by 13.35% to $137.3 million in 2023, then decreased by 10.61% to $122.7 million in 2024, then soared by 36.43% to $167.4 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Cash & Current Investments are $167.4 million (Q4 2025), $147.9 million (Q3 2025), and $117.8 million (Q2 2025).